Drug Targets – Products
Good Data. Rich Insights. More Discoveries.
Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.
Orbit Discovery and Evergreen Discovery Collaborate To Discover Peptides for Targeting Radiopharmaceuticals
Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase II Randomized Trial
Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.
Carterra Launches the LSAXT High-Throughput SPR Biosensor at SLAS2023
Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.
GenNext Technologies Appoints Dr. Lisa Jones of UCSD to the Role of Chief Science Officer
GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.
App Note / Case Study
Consistency is Key to Further Drug Discovery Research
Energy metabolism plays a central role in a wide variety of cellular and physiological processes. Therefore, a deep understanding of how disruption to energy metabolism impacts cells can help in therapeutic drug discovery and development.
Foundational Partnership With Paradigm4 Enables Alnylam Pharmaceuticals To Accelerate RNAi-Based Drug Target Discovery
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Ubiquigent Appoints Dr. Sheelagh Frame, CSO, to its Board of Directors
Ubiquigent Limited today announced the appointment of Dr. Sheelagh Frame, Chief Scientific Officer, to the Company’s Board of Directors.
MACSima™ Imaging Platform – The Next Level of Context in Spatial Biology
The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.